Ocular Melanoma: A Look at the Promising Drugs in Development

Ocular melanoma is a rare form of eye cancer affecting 5 out of every million adults. While uncommon, it is the most prevalent primary eye cancer among adults, meaning it originated in the eye rather than spreading from elsewhere. Researchers are actively working to develop new treatments for this disease, with 94 drugs currently in development across various phases of clinical trials. The majority of these drugs are in Phase II trials, indicating significant progress in the search for effective therapies. This research focuses on various drug targets and mechanisms of action, including immune checkpoint inhibitors and targeted therapies. The goal is to improve treatment outcomes and offer hope to patients battling this challenging condition.